France's Median Technologies Q3 revenue rises to record high

Median Technologies SA

29/10/2026 16:57

Overview
France medical imaging firm's Q3 revenue rose 14.4% yr/yr to record €6.7 mln
Order backlog hit record €90.9 mln at end-September, up 23.5% yr/yr

Outlook
Company expects first eyonis LCS revenues in the first half of 2027
Company says cash runway extends through H1 2028, with potential extension to H1 2029 if warrants exercised

Result Drivers
LARGE PROJECT WIN - Co secured €8.4 mln global Phase III oncology imaging project, contributing to order backlog and revenue growth
BIOPHARMA DEMAND - Sustained demand from biopharma clients drove iCRO business momentum and backlog growth
CHINA GROWTH - Revenue growth in H1 2026 mainly driven by China, up 10% yr/yr and accounting for 39% of group revenue

Company press release: ID:nBw7pCzsGa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
 
EUR 6.7 mln
 
Q3 iCRO Order Backlog
 
EUR 90.9 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Median Technologies SA is €12.95, about 196.3% above its October 28 closing price of €4.37

Reuters Recommended Reads
Oct 28 - Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth
Oct 28 - Joinn Laboratories Q3 revenue rises on industry recovery
Oct 27 - Healthcare data firm IQVIA Q3 revenue beats on strong bookings

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)